Logo

PPBT

Purple Biotech Ltd.

PPBT

Purple Biotech Ltd. • NASDAQ
$0.83 ▲ 4.08% (+0.03)
Market Cap $11302
52w High $13.95
52w Low $0.53
Dividend Yield 0%
P/E -0.02
Volume 143.56K
Outstanding Shares 13.68K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.315M ▲ $-1.309M ▼ 0% $-58 ▲ $-1.248M ▼
Q2-2025 $0 $1.236M ▼ $-1.085M ▼ 0% $-80 ▼ $-1.042M ▼
Q1-2025 $0 $1.406M ▲ $-453K ▼ 0% $-34 ▼ $-376K ▲
Q4-2024 $0 $976K ▼ $-410K ▲ 0% $-0.2 ▲ $-886K ▼
Q3-2024 $0 $2.133M $-663K 0% $-0.38 $-108K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $10.454M ▲ $39.061M ▲ $6.246M ▲ $32.773M ▲
Q2-2025 $5.919M ▼ $34.378M ▼ $2.329M ▼ $32.005M ▼
Q1-2025 $7.087M ▼ $35.594M ▼ $2.898M ▼ $32.648M ▼
Q4-2024 $8.524M ▲ $37.038M ▲ $4.127M ▼ $32.86M ▲
Q3-2024 $6.3M $35.105M $5.638M $29.411M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.309M ▼ $-1.009M ▲ $325.125K ▲ $5.593M ▲ $4.856M ▲ $0 ▲
Q2-2025 $-1.089M ▼ $-1.544M ▲ $107K ▼ $366K ▲ $-1.036M ▲ $-1.546M ▲
Q1-2025 $-456K ▼ $-1.978M ▲ $257K ▲ $103K ▼ $-1.629M ▼ $-1.978M ▲
Q4-2024 $-415K ▲ $-2.014M ▲ $38K ▼ $3.939M ▲ $1.963M ▲ $-2.014M ▲
Q3-2024 $-668K $-3.295M $72K $2.134M $-1.086M $-3.295M

Five-Year Company Overview

Income Statement

Income Statement Purple Biotech is still a pure R&D biotech story with no product revenue yet. The income statement is driven almost entirely by research and operating expenses, which have led to steady but moderate losses each year. Those losses appear reasonably controlled rather than rapidly escalating, which suggests some spending discipline. The headline per‑share loss recently looks much larger mainly because of reverse stock splits, not because the business suddenly deteriorated. Overall, the income statement reflects a typical clinical‑stage biotech: no sales, ongoing R&D costs, and reliance on future milestones for any path to profitability.

Balance Sheet

Balance Sheet The balance sheet is small but relatively clean. The company carries no financial debt, which reduces interest burden and refinancing risk. Assets are limited and dominated by cash and R&D‑related items, with equity providing the main funding base. Over the past few years, total assets and equity have drifted down as losses accumulate, which is standard for a pre‑revenue biotech. The key takeaway is that Purple Biotech has a simple, low‑leverage structure, but also a finite financial runway that will likely require new capital or partnerships over time.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting funding of clinical trials and R&D without any offsetting product income. Capital spending is minimal, so free cash flow closely mirrors the operating cash burn. The burn level is not extreme in absolute terms, but it is steady, meaning the company’s ability to keep advancing its pipeline depends on access to new funding sources. Investors should view the cash flow profile as typical for a clinical‑stage biotech: money flows out to support development, and the timing and size of any future inflows are uncertain and tied to trial outcomes and deals.

Competitive Edge

Competitive Edge Purple Biotech operates in a very competitive oncology space but is focused on less crowded, more specialized areas. Its position is built around first‑in‑class mechanisms aimed at drug resistance and immune evasion, rather than “me‑too” products. Early clinical signals, particularly in hard‑to‑treat cancers, help differentiate it from some peers. At the same time, it competes against much larger pharma and biotech companies with deeper resources, and it faces the usual binary risks of clinical and regulatory setbacks. In short, the company has a differentiated scientific angle but competes in a high‑risk, high‑intensity environment.

Innovation and R&D

Innovation and R&D Innovation is the core strength here. Purple Biotech is advancing three distinct platforms: a small molecule to tackle resistance pathways, an antibody against a novel immune checkpoint, and a tri‑specific antibody platform designed for more targeted and safer immune activation. The use of biomarker‑defined patient groups, dual‑target inhibition, and “masked” T‑cell engagers shows a clear emphasis on next‑generation oncology science. Recent clinical results and manufacturing progress support that the technology works not just in theory but in practice. However, these are still early‑ to mid‑stage programs, so there is meaningful uncertainty around ultimate efficacy, safety, and commercial viability.

Summary

Purple Biotech is a classic clinical‑stage oncology company: no current revenue, controlled but ongoing losses, a clean balance sheet without debt, and a steady cash burn supporting ambitious R&D. Its real value driver is a differentiated pipeline targeting drug resistance, immune checkpoints, and tri‑specific antibody approaches, with some encouraging mid‑stage data in very tough cancer types. The main opportunities lie in successful progression of trials, potential regulatory paths, and future partnerships or licensing deals. The main risks are the usual ones for this sector: trial failures, delays, funding needs, and intense competition from larger players. Overall, this is an innovation‑heavy, financially lean biotech where future outcomes hinge on clinical and strategic execution rather than current financial performance.

NEWS

November 14, 2025 · 8:00 AM UTC

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

October 29, 2025 · 7:33 AM UTC

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Read more

October 20, 2025 · 4:00 PM UTC

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Read more

September 5, 2025 · 4:00 PM UTC

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Read more